Skip to main content

Articles

Page 30 of 34

  1. In this study, we evaluated the safety and pharmacodynamic effects of the Fc-inactivated anti-β-amyloid (anti-Aβ) monoclonal antibody GSK933776 in patients with mild Alzheimer’s disease and mild cognitive impa...

    Authors: Thomas Leyhe, Niels Andreasen, Monica Simeoni, Arno Reich, Christine AF von Arnim, Xin Tong, Astrid Yeo, Shahid Khan, Amy Loercher, Michelle Chalker, Charles Hottenstein, Henrik Zetterberg, Jan Hilpert and Prafull Mistry
    Citation: Alzheimer's Research & Therapy 2014 6:19
  2. This review summarises the findings and applications from neuroimaging studies in dementia with Lewy bodies (DLB), highlighting key differences between DLB and other subtypes of dementia. We also discuss the i...

    Authors: Elijah Mak, Li Su, Guy B Williams and John T O’Brien
    Citation: Alzheimer's Research & Therapy 2014 6:18
  3. TMEM106B is a transmembrane glycoprotein of unknown function located within endosome/lysosome compartments expressed ubiquitously in various cell types. Previously, the genome-wide association study (GWAS) ide...

    Authors: Jun-ichi Satoh, Yoshihiro Kino, Natsuki Kawana, Yoji Yamamoto, Tsuyoshi Ishida, Yuko Saito and Kunimasa Arima
    Citation: Alzheimer's Research & Therapy 2014 6:17
  4. The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly i...

    Authors: Lars Lannfelt, Christer Möller, Hans Basun, Gunilla Osswald, Dag Sehlin, Andrew Satlin, Veronika Logovinsky and Pär Gellerfors
    Citation: Alzheimer's Research & Therapy 2014 6:16
  5. The progressive dementia that is characteristic of Alzheimer’s disease is associated with the accumulation of amyloid-beta (Aβ) peptides in extracellular plaques and within neurons. Aβ peptides are targeted to...

    Authors: Charlotte Simmons, Victoria Ingham, Alun Williams and Clive Bate
    Citation: Alzheimer's Research & Therapy 2014 6:15
  6. Many progressive neurodegenerative diseases, including Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, and frontotemporal lobe dementia, are associated with the formati...

    Authors: Faisal Fecto, Y Taylan Esengul and Teepu Siddique
    Citation: Alzheimer's Research & Therapy 2014 6:13
  7. “Partners in Dementia Care” (PDC) tested the effectiveness of a care-coordination program integrating healthcare and community services and supporting veterans with dementia and their caregivers. Delivered via...

    Authors: David M Bass, Katherine S Judge, ALynn Snow, Nancy L Wilson, Robert O Morgan, Katie Maslow, Ronda Randazzo, Jennifer A Moye, Germaine L Odenheimer, Elizabeth Archambault, Richard Elbein, Paul Pirraglia, Thomas A Teasdale, Catherine A McCarthy, Wendy J Looman and Mark E Kunik
    Citation: Alzheimer's Research & Therapy 2014 6:9
  8. Tau pathology is associated with a number of age-related neurodegenerative disorders. Few treatments have been demonstrated to diminish the impact of tau pathology in mouse models and none are yet effective in...

    Authors: Maj-Linda Selenica, Leif Benner, Steven B Housley, Barbara Manchec, Daniel C Lee, Kevin R Nash, Jay Kalin, Joel A Bergman, Alan Kozikowski, Marcia N Gordon and Dave Morgan
    Citation: Alzheimer's Research & Therapy 2014 6:12
  9. The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies hav...

    Authors: Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura and Victor L Villemagne
    Citation: Alzheimer's Research & Therapy 2014 6:11
  10. Sports-related concussions are one of the major causes of mild traumatic brain injury. Although most patients recover completely within days to weeks, those who experience repetitive brain trauma (RBT) may be ...

    Authors: Thomas SC Ng, Alexander P Lin, Inga K Koerte, Ofer Pasternak, Huijun Liao, Sai Merugumala, Sylvain Bouix and Martha E Shenton
    Citation: Alzheimer's Research & Therapy 2014 6:10
  11. Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, afflicting more than one-third of people over the age of 85. While many therapies for AD are in late-stage clinical testing, rational drug ...

    Authors: Haakon B Nygaard, Christopher H van Dyck and Stephen M Strittmatter
    Citation: Alzheimer's Research & Therapy 2014 6:8
  12. Alzheimer’s disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protei...

    Authors: Bengt Winblad, Ana Graf, Marie-Emmanuelle Riviere, Niels Andreasen and J Michael Ryan
    Citation: Alzheimer's Research & Therapy 2014 6:7
  13. Cerebrospinal fluid (CSF) amyloid-beta 38 (Aβ38), 40 (Aβ40), 42 (Aβ42) and total tau (T-tau) are finding increasing utility as biomarkers of Alzheimer’s disease (AD). The purpose of this study was to determine...

    Authors: Jamie Toombs, Ross W Paterson, Jonathan M Schott and Henrik Zetterberg
    Citation: Alzheimer's Research & Therapy 2014 6:5
  14. Dementia is currently diagnosed based on clinical symptoms and signs, but significant brain damage has already occurred by the time a clinical diagnosis of dementia is made, and it is increasingly recognized t...

    Authors: Galit Weinstein and Sudha Seshadri
    Citation: Alzheimer's Research & Therapy 2014 6:6
  15. Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease that occurs in association with repetitive traumatic brain injury experienced in sport and military service. In most instances,...

    Authors: Thor D Stein, Victor E Alvarez and Ann C McKee
    Citation: Alzheimer's Research & Therapy 2014 6:4
  16. Perhaps more definitively than any other class of novel Alzheimer’s disease (AD) therapy, pre-clinical studies in mouse models of amyloid β (Aβ) deposition have established the disease-modifying potential of a...

    Authors: Todd E Golde
    Citation: Alzheimer's Research & Therapy 2014 6:3
  17. Previous work has demonstrated the efficacy of irradiating tissue with red to infrared light in mitigating cerebral pathology and degeneration in animal models of stroke, traumatic brain injury, parkinsonism a...

    Authors: Sivaraman Purushothuman, Daniel M Johnstone, Charith Nandasena, John Mitrofanis and Jonathan Stone
    Citation: Alzheimer's Research & Therapy 2014 6:2
  18. Microtubule-associated protein tau encoded by the MAPT gene binds to microtubules and is important for maintaining neuronal morphology and function. Alternative splicing of MAPT pre-mRNA generates six major tau i...

    Authors: Melissa E Murray, Naomi Kouri, Wen-Lang Lin, Clifford R Jack Jr, Dennis W Dickson and Prashanthi Vemuri
    Citation: Alzheimer's Research & Therapy 2014 6:1
  19. Growing evidence suggests that vascular perturbation plays a critical role in the pathogenesis of Alzheimer’s disease (AD). It appears to be a common feature in addition to the classic pathological hallmarks o...

    Authors: Wilfred A Jefferies, Katherine A Price, Kaan E Biron, Franz Fenninger, Cheryl G Pfeifer and Dara L Dickstein
    Citation: Alzheimer's Research & Therapy 2013 5:64
  20. The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as ...

    Authors: Steven Ferris, Stella Karantzoulis, Monique Somogyi and Xiangyi Meng
    Citation: Alzheimer's Research & Therapy 2013 5:63
  21. Symptomatic treatments for Alzheimer’s disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for impro...

    Authors: Pierre Jean Ousset, Julien Delrieu and Bruno Vellas
    Citation: Alzheimer's Research & Therapy 2013 5:62
  22. γ-Secretase-mediated production of amyloid β from the amyloid precursor protein is recognized as a central player in the neuropathogenesis of Alzheimer’s disease (AD). One of the most peculiar features of this...

    Authors: Nathalie Jurisch-Yaksi and Wim Annaert
    Citation: Alzheimer's Research & Therapy 2013 5:61
  23. The oligomer cascade hypothesis, which states that oligomers are the initiating pathologic agents in Alzheimer’s disease, has all but supplanted the amyloid cascade hypothesis, which suggested that fibers were...

    Authors: Eric Y Hayden and David B Teplow
    Citation: Alzheimer's Research & Therapy 2013 5:60
  24. The amyloid-β42 (Aβ42) peptide plays a crucial role in the pathogenesis of Alzheimer’s disease (AD), the most common neurodegenerative disorder affecting the elderly. Over the past years, several approaches and c...

    Authors: Sabrina Meister, Iavor Zlatev, Julia Stab, Dominic Docter, Sandra Baches, Roland H Stauber, Mordechai Deutsch, Reinhold Schmidt, Stefan Ropele, Manfred Windisch, Klaus Langer, Sylvia Wagner, Hagen von Briesen, Sascha Weggen and Claus U Pietrzik
    Citation: Alzheimer's Research & Therapy 2013 5:51
  25. Souvenaid® containing Fortasyn® Connect is a medical food designed to support synapse synthesis in persons with Alzheimer’s disease (AD). Fortasyn Connect includes precursors (uridine monophosphate; choline; p...

    Authors: Raj C Shah, Patrick J Kamphuis, Sue Leurgans, Sophie H Swinkels, Carl H Sadowsky, Anke Bongers, Stephen A Rappaport, Joseph F Quinn, Rico L Wieggers, Philip Scheltens and David A Bennett
    Citation: Alzheimer's Research & Therapy 2013 5:59
  26. Fluid biomarkers improve the diagnostic accuracy in dementia and provide an objective measure potentially useful as a therapeutic response in clinical trials. The role of fluid biomarkers in patient care is a ...

    Authors: Pedro Rosa-Neto, Ging-Yuek Robin Hsiung and Mario Masellis
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S8

    This article is part of a Supplement: Volume 5 Supplement 1

  27. Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer’s disease is during the preclinical phase of the disease. This is a phase when individuals are defined as ...

    Authors: Dorene M Rentz, Mario A Parra Rodriguez, Rebecca Amariglio, Yaakov Stern, Reisa Sperling and Steven Ferris
    Citation: Alzheimer's Research & Therapy 2013 5:58
  28. The clinical features of Alzheimer’s disease (AD) overlap with a number of other dementias and conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable ...

    Authors: Noemí Esteras, Carolina Alquézar, Ana de la Encarnación, Alberto Villarejo, Félix Bermejo-Pareja and Ángeles Martín-Requero
    Citation: Alzheimer's Research & Therapy 2013 5:55
  29. Autophagy serves as the sole catabolic mechanism for degrading organelles and protein aggregates. Increasing evidence implicates autophagic dysfunction in Alzheimer’s disease (AD) and other neurodegenerative d...

    Authors: Miranda E Orr and Salvatore Oddo
    Citation: Alzheimer's Research & Therapy 2013 5:53
  30. The aim of this study was to explore the predictors of decline in walking ability in patients with Alzheimer’s disease (AD).

    Authors: Yves Rolland, Christelle Cantet, Philipede Souto Barreto, Matteo Cesari, Gabor Abellan van Kan and Bruno Vellas
    Citation: Alzheimer's Research & Therapy 2013 5:52
  31. Intraparenchymal injections of the immunotoxin 192-IgG-saporin into medial septum and nucleus basalis magnocellularis causes a selective depletion of basal forebrain cholinergic neurons. Thus, it represents a ...

    Authors: Debora Cutuli, Paola De Bartolo, Paola Caporali, Anna Maria Tartaglione, Diego Oddi, Francesca Romana D’Amato, Annalisa Nobili, Marcello D’Amelio and Laura Petrosini
    Citation: Alzheimer's Research & Therapy 2013 5:50
  32. Accumulation and aggregation of the microtubule-associated protein tau are a pathological hallmark of neurodegenerative disorders such as Alzheimer’s disease (AD). In AD, tau becomes abnormally phosphorylated ...

    Authors: Amy M Pooler, Manuela Polydoro, Susanne Wegmann, Samantha B Nicholls, Tara L Spires-Jones and Bradley T Hyman
    Citation: Alzheimer's Research & Therapy 2013 5:49
  33. The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer’s disease (AD). Its primary aims are to investigate the tempora...

    Authors: Krista L Moulder, B Joy Snider, Susan L Mills, Virginia D Buckles, Anna M Santacruz, Randall J Bateman and John C Morris
    Citation: Alzheimer's Research & Therapy 2013 5:48
  34. The neuronal loss in Alzheimer disease (AD) has been described to affect grey matter in the cerebral cortex. However, in the elderly, AD pathology is likely to occur together with subcortical axonal degenerati...

    Authors: Tobias Skillbäck, Henrik Zetterberg, Kaj Blennow and Niklas Mattsson
    Citation: Alzheimer's Research & Therapy 2013 5:47
  35. Knowledge of longitudinal progression in mild Alzheimer’s disease (AD) is required for the evaluation of disease-modifying therapies. Our aim was to observe the effects of long-term cholinesterase inhibitor (C...

    Authors: Carina Wattmo, Åsa K Wallin and Lennart Minthon
    Citation: Alzheimer's Research & Therapy 2013 5:44
  36. Increased knowledge of the biology of synaptic function has led to the development of novel cognitive-enhancing therapeutic strategies with the potential for increased efficacy and safety. This editorial highl...

    Authors: Diana W Shineman, Aaron J Carman, Penny A Dacks, Rachel F Lane and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2013 5:45
  37. APOE, which encodes apolipoprotein E, is the most prevalent and best established genetic risk factor for late-onset Alzheimer’s disease. Current understanding of Alzheimer’s disease pathophysiology posits an impo...

    Authors: Andrew B Wolf, Jon Valla, Guojun Bu, Jungsu Kim, Mary Jo LaDu, Eric M Reiman and Richard J Caselli
    Citation: Alzheimer's Research & Therapy 2013 5:38
  38. The possibility to map amyloid-beta, the Alzheimer’s disease hallmark protein, in vivo opens the application for amyloid imaging in clinical trials with disease-modifying agents. Monitoring change in amyloid b...

    Authors: Rik Ossenkoppele, Niels D Prins and Bart NM van Berckel
    Citation: Alzheimer's Research & Therapy 2013 5:36
  39. Cognitive impairments, and particularly memory deficits, are a defining feature of the early stages of Alzheimer's disease and vascular dementia. Interventions that target these cognitive deficits and the asso...

    Authors: Alex Bahar-Fuchs, Linda Clare and Bob Woods
    Citation: Alzheimer's Research & Therapy 2013 5:35